Literature DB >> 9692784

Agonist action at D2(long) dopamine receptors: ligand binding and functional assays.

B Gardner1, P G Strange.   

Abstract

1. The activities of a range of agonists at D2(long) dopamine receptors expressed in CHO cells have been determined in ligand binding and in a functional assay, the stimulation of [35S]-GTPgammaS binding. 2. For several agonists (apomorphine, dopamine, pergolide, quinpirole, NPA, ropinirole, talipexole) binding in the absence of added guanine nucleotides was best described in terms of interaction at higher and lower affinity states, whereas for other agonists (bromocriptine, DHEC, lisuride, 3-PPP) a one binding site model was a good description of the data. In the presence of GTP (100 microM) all agonist binding data were best described by a one site model. 3. All of the agonists tested increased [35S]-GTPgammaS binding above the basal level and the maximal effects and potencies of the agonists in this test were different. There was no clear relation between the ability of an agonist to stabilize the formation of the ternary complex of agonist/receptor/G-protein and the maximal activity of the agonist or the amplification factor (ratio of dissociation constant for binding to receptor to EC50 in functional assay). 4. A comparison was made between the profiles of the D2(short) and D2(long) receptor isoforms in these assays.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692784      PMCID: PMC1565475          DOI: 10.1038/sj.bjp.0701926

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

Review 1.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI.

Authors:  Christin Y Sander; Jacob M Hooker; Ciprian Catana; Bruce R Rosen; Joseph B Mandeville
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

3.  A practical process for the preparation of [(32)P]S1P and binding assay for S1P receptor ligands.

Authors:  Adam J Rosenberg; Hui Liu; Zhude Tu
Journal:  Appl Radiat Isot       Date:  2015-04-17       Impact factor: 1.513

Review 4.  Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?

Authors:  Mette Skinbjerg; David R Sibley; Jonathan A Javitch; Anissa Abi-Dargham
Journal:  Biochem Pharmacol       Date:  2011-09-16       Impact factor: 5.858

5.  Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5-HT1A serotonin receptor.

Authors:  J Tracy Alder; Uli Hacksell; Philip G Strange
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

6.  Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.

Authors:  H Lin; S G N Saisch; P G Strange
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

Review 7.  Ropinirole: a review of its use in the management of Parkinson's disease.

Authors:  A J Matheson; C M Spencer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

8.  Mechanisms of G protein activation via the D2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation.

Authors:  K Quirk; D J Roberts; P G Strange
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

9.  A chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates.

Authors:  Andrea L Johnstone; Gillian W Reierson; Robin P Smith; Jeffrey L Goldberg; Vance P Lemmon; John L Bixby
Journal:  Mol Cell Neurosci       Date:  2012-05-03       Impact factor: 4.314

10.  Cdk5 phosphorylates dopamine D2 receptor and attenuates downstream signaling.

Authors:  Jaehoon Jeong; Young-Un Park; Dae-Kyum Kim; Saebom Lee; Yongdo Kwak; Seol-Ae Lee; Haeryun Lee; Yoo-Hun Suh; Yong Song Gho; Daehee Hwang; Sang Ki Park
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.